Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists
The relaxin receptor RXFP1 is a therapeutic target owing to its potential benefits in the treatment of fibrosis and heart failure. Protein and small-molecule agonists are currently in midstage clinical trials for various forms of heart disease. In this work, we present three cryo–electron microscopy structures of RXFP1: ligand-free, bound to the native agonist relaxin-2, and bound to the small-molecule drug candidate AZD5462. These structures reveal that relaxin-2 engages the receptor’s ectodomain, whereas AZD5462 binds to the transmembrane domain. Together with hydrogen-deuterium exchange mass spectrometry, we show that relaxin-2 induces reorganization of the linker domain into a helical secondary structure. By contrast, AZD5462 stabilizes an active conformation through a distinct set of conformational rearrangements. Altogether, our findings define divergent activation mechanisms for protein and small-molecule agonists of RXFP1.
Authors
- Mark W. Grinstaff (ORCID: https://orcid.org/0000-0002-5453-3668)
- Xunan Wang (ORCID: https://orcid.org/0009-0001-9467-7914)
- Pengxiang Shen
- James Osei‐Owusu (ORCID: https://orcid.org/0000-0002-8676-4444)
- Xiaojing Cong (ORCID: https://orcid.org/0000-0002-5051-2392)
- Sarah C. Erlandson
- Jeffrey S. Smith (ORCID: https://orcid.org/0000-0003-2840-2899)
- Chérine Bechara (ORCID: https://orcid.org/0000-0002-5539-6327)
- Amanda K. Williamson (ORCID: https://orcid.org/0000-0002-1840-4199)
- Andrew C. Kruse (ORCID: https://orcid.org/0000-0002-1467-1222)
- Tristan Girbau (ORCID: https://orcid.org/0009-0006-2402-4703)
- Daniel Kahne
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Centre National de la Recherche Scientifique (FR)
- Harvard University (US)
- Inserm (FR)
- Université de Montpellier (FR)
- Institut de Génomique Fonctionnelle (FR)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Science
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1126/science.aei0135
- Citations
- 1
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.12
Funders
- Howard Hughes Medical Institute
- Agence Nationale de la Recherche
- Région Occitanie Pyrénées-Méditerranée
- National Institutes of Health
- European Regional Development Fund
- National Institute of Arthritis and Musculoskeletal and Skin Diseases